The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer
Summary
The purpose of this study is to see whether using the copper-64 (64Cu) or zirconium-89 (89Zr) radiolabeled PSMA-targeting C' dot tracer, termed 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots or 89Zr-DFO-PSMAi-PEG-Cy5.5-C' dots, is a safe way to identify tumor cells before and during surgery for prostate cancer. The researchers want to determine whether pre-operative PET/MRI scans and intra-operative optical imaging performed in prostate cancer patients after the injection of one of these investigational tracers more accurately localizes cancerous deposits within the surgical bed as compared with conventional imaging scans alone. The researchers will study how the tracer travels through your body and where it is distributed. This study is the first time that the tracer will be used in patients undergoing surgery for prostate cancer.
Timeline
- Start
- 2021-02-17
- Primary completion
- 2027-11
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | (64Cu)-NOTA-PSMAi-PEG-Cy5.5-C' dot tracer | Diagnostic / imaging agent | 6 unknown | Intravenous |
| Subject | (64Cu)-NOTA-PSMAi-PEG-Cy5.5-C' dot tracer | Diagnostic / imaging agent | 7 unknown | Intravenous |
| Subject | 89Zr-DFO-PSMAi-PEG-Cy5.5-C' dots | Diagnostic / imaging agent | 5 unknown | Intravenous |
| Subject | 89Zr-DFO-PSMAi-PEG-Cy5.5-C' dots | Diagnostic / imaging agent | 7 unknown | Intravenous |